Do pharmaceutical investment from which to break through the bottleneck of investment

Drug investment is currently the hot spot in the pharmaceutical industry. “What to do if the investment is not successful” and “how to break through the bottleneck of investment promotion” have become the issues that companies are most concerned about. Under such circumstances, companies and marketers have turned their attention to the improvement of investment promotion techniques and changes in investment methods. They have often overlooked market research and problem solving based on the sustainable development of enterprises. This is not conducive to enterprises. Growing up with dealers. How can we find the key to opening up the transformation and development of pharmaceutical companies and realizing dealers to bring continuous value to the company? Only in this way can we increase the attractiveness of enterprises and gradually change the difficult state of drug investment at this stage.

First of all, the fact that drug investment enterprises grasp the actual situation of the drug agency information market in time is the basis for enterprises to formulate policies and carry out effective market management. However, many pharmaceutical companies now have very weak foundations in this regard and increase the closeness of cooperation with distributors. The transformation from a simple interest combination to a common development based on the identification of corporate culture is the best state of the manufacturer's relationship pursued by the company. However, the formation of this state requires a process that also requires the reform of the pharmaceutical investment enterprise itself.

Secondly, in the management of pharmaceutical agent information, enterprises should establish a detailed management archive with the dealer’s market behavior as the main body, including the main products operated by the distributors and their market performance, investment status, staffing, network coverage, and credit status. According to the development of the market and changes in dealers in a timely manner to make up for, based on this, adjust the channel strategy and related policies. This is different from the simple classification of dealers. It needs to focus on the dealer’s market behavior and incorporate the realities and developments of dealers into management. This is an inevitable transition from extensive to fine-scale market operations for pharmaceutical companies.

Last but not least, creating more value marketing for distributors is to continuously create value for customers. This is the basis for increasing the close cooperation with dealers in the pharmaceutical companies that use pharmaceuticals as the main means of market operations. Creating value for distributors does not equate to lowering supply prices and giving more rebates. It is a strategy that truly skews to the market, promotes product sales, and provides distributors with sales skills according to the needs of dealers at different stages of development. , product knowledge training, product line planning, market planning and direction of development guidance.